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Objectives: We sought to investigate the effectiveness of glucocorticoid adminis-
tration or continuous venovenous hemodiafiltration on endothelin and corticotropin-
releasing factor release or clearance during prolonged fetal cardiac bypass and on
the overall performance of fetuses.
Methods: Circulating endothelin 1, 2, and 3 and corticotropin-releasing factor levels
were measured in fetal ewes during a 60-minute cardiac bypass period performed
with an inline axial flow pump. Blood samples were collected before, during, and 90
minutes after cardiac bypass. Animals were divided into 4 groups. The betametha-
sone group (n 6) received maternal treatment with 12 mg of betamethasone 1 and
2 days before the experiment. The methylprednisolone group (n  5) received fetal
treatment with 40 mg/kg intravenous methylprednisolone at the beginning of cardiac
bypass. The continuous venovenous hemodiafiltration group (n  4) underwent
continuous venovenous hemodiafiltration with a 0.3-m2 polysulfone filter during
cardiac bypass. The final group was the control group (n  4).
Results: Maternal steroid pretreatment failed to decrease endothelin or corticotrop-
in-releasing factor production when compared with levels in the control animals.
Fetal treatment with methylprednisolone produced a significant decrease in endo-
thelin 2 production during cardiac bypass (P  .02) and endothelin 1 production at
the end of the experiment (P  .02). Continuous venovenous hemodiafiltration
blocked completely the increase of endothelin and corticotropin-releasing factor
levels during cardiac bypass (P  .02), which was maintained 90 minutes after
cardiac bypass. Acid-base balance was preserved during cardiac bypass by the
continuous venovenous hemodiafiltration but worsened after disconnection of the
extracorporeal circuit, whereas animals treated with methylprednisolone had better
pH, PaCO2, and bicarbonate levels by the end of the experiment. The overall
tolerance of the procedure was better in the continuous venovenous hemodiafiltra-
tion group during cardiac bypass and in the methylprednisolone group at the end of
the experiment.
Conclusions: Continuous venovenous hemodiafiltration provides sustained stability
of endothelin levels during fetal cardiac bypass. This technique might help, in
association with fetal steroid treatment, to contain the inflammatory response
leading to postbypass placental dysfunction.
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Placental dysfunction during experimental fetalcardiac surgery is a major obstacle to success-ful in utero extracorporeal cardiac bypass(CB).1-3 Released interleukins and other in-flammatory or vasoactive substances havebeen shown to play an important role in the
dysfunction of the fetoplacental unit during CB.4-6 Despite
miniaturized extracorporeal circuits resulting in signifi-
cantly improved fetal survival by reducing the extracorpo-
real surface and avoiding transfusion of blood components,
inflammatory reactions and related fetoplacental dysfunc-
tions still occur.7,8 Glucocorticoid agents administered be-
fore fetal CB have been shown to improve placental func-
tion. Possible involved mechanisms include inhibition of
vasoconstrictive prostaglandin production and inhibition of
proinflammatory cytokine synthesis.9,10 In recent years, he-
mofiltration techniques have been diffusely adopted during
pediatric cardiopulmonary bypass to reduce the inflamma-
tory response to the bypass itself, to help clear circulating
cytokines produced during the procedure, or both.11-16
On these bases, we have conducted experiments to ana-
lyze the effect of glucocorticoid administration and contin-
uous venovenous hemodiafiltration (CVVHD) on endothe-
lin and corticotropin-releasing factor (CRF) plasma
concentrations during prolonged fetal CB and on the overall
performance of the fetoplacental unit function during and
after the procedure. The experimental set-up included a
60-minute period of fetal CB performed by using a minia-
turized circuit with an inline axial flow pump without an
extracorporeal oxygenator, followed by a 90-minute obser-
vation period.
Methods
Animals
Animals were divided into 4 groups. In the betamethasone group
(n  6) pregnant ewes were pretreated with 2 doses of 12 mg of
intramuscular betamethasone 1 and 2 days, respectively, before the
experiment. In the methylprednisolone group (n  5) fetuses
received a bolus of 40 mg/kg intravenous methylprednisolone just
before CB. In the CVVHD group (n  4) CVVHD was performed
during the entire CB. The final group was the control group (n 
4).
Surgical Procedure
Nineteen pregnant Comisana ewes between 120 and 130 days of
gestation were fasted for 36 to 48 hours and premedicated by
means of intramuscular injection with 10 mg/kg ketamine, 0.01
mg/kg buprenorphine, and 0.02 mg/kg atropine. Induction of an-
esthesia was achieved with 2% inspired halothane supplied
through a mask with a Fluotec vaporizer (Ohmeda Heath Care,
West Yorkshire, England). After endotracheal intubation, epidural
anesthesia was performed with 0.3 mg/kg of a 1% tetracaine
hydrochloride solution. Anesthesia was then maintained with con-
tinuous intravenous infusion of ketamine at a rate of 5 mg · kg1
· h1. Ewes were slightly hyperventilated with 100% oxygen to
maintain PaCO2 blood gas levels at less than 30 mm Hg. Intra-
arterial and intravenous access were obtained to monitor maternal
arterial blood pressure and blood gases and to infuse fluids during
the surgical procedures.
The uterus was exposed through an extended midline laparot-
omy, and the number and orientation of the fetus or fetuses was
determined. A short hysterotomy was made at the level of the
upper chest of the selected fetus. The right forelimb was then
extracted to cannulate a peripheral vein. Intravenous fetal anesthe-
sia was then started with a bolus of ketamine (10 mg/kg) and
maintained with an infusion of ketamine (12 mg · kg1 · h1).
After exposure of the sternum, an extended midline sternotomy
was performed. The right common carotid artery was dissected and
cannulated for monitoring fetal arterial blood pressure and heart
rate and for blood sampling. The right internal jugular vein was
cannulated to infuse fluids at a constant rate of 20 mL · kg1 · h1.
The pericardium was then opened, and purse-string sutures were
placed on the main pulmonary artery and on the right appendix.
Heparin (300 U/kg) was administered intravenously before
arteriovenous cannulation with a 16F angled-tip venous cannula
and a 3.5-mm arterial cannula, both primed by means of retrograde
fetal blood filling. The arterial and venous cannulae were then
connected to a miniaturized bypass circuit by using an inline axial
flow pump (Hemopump, modified model HP24 sternotomy pump;
Medtronic Inc, Grand Rapids, Mich), and the CB was run at a flow
rate of 300 mL · kg1 · min1 up to a maximal flow of 1 L/min
(see Appendix A).
After 60 minutes, the bypass was discontinued, the pulmonary
arterial cannula was removed, and the priming volume was rein-
fused through the venous cannula. The atrial cannula was then
removed. Heparin was not reversed.
After 90 minutes off pump, the experiment was terminated. The
ewe and fetus were killed with an overdose (200 mg/kg) of
intravenous sodium pentobarbital. Fetuses were then weighed to
control the initial fetal weight estimation.
All animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals of the Italian
Ministry of Health.
CVVHD
Fetuses of group 3 were treated with CVVHD without net ultra-
filtration during the entire CB period. CVVHD was performed
with a 0.3-m2 polysulfone filter (Aquamax HF 03; Edwards Life-
sciences, S.A., Saint-Prex, Switzerland) primed with 5% human
plasma protein solution. The system was connected in countercur-
rent with the bypass circuit to the venous arm. The blood flow rate
was 150 mL/min, and the ultrafiltration balance was set to 0. Blood
flow and dialysis fluid balance were controlled by a BM 25
hemofiltration apparatus (Edwards Lifesciences). Fluid balance
accuracy declared by the manufacturer is 0.5%. HF 100 hemo-
filtration solution (Gambro S.p.a, Parma, Italy) was used at a flow
rate of 4500 mL/h, containing 140 mmol/L Na, 1.5 mmol/L K, 2
mmol/L Ca, 0.75 mmol/L Mg, 108 mmol/L Cl, 4 mmol/L CH3, 35
mmol/L HCO3, and 5.55 mmol/L glucose.
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Data Acquisition
Maternal and fetal heart rates and arterial blood pressures (Tru-
wave PX-600F pressure transducers, Edwards Lifesciences) were
monitored continuously during the entire study. Fetal hemody-
namic parameters were recorded after heparin administration, be-
fore positioning the bypass cannulae (T0), during CB at 30 and 60
minutes (T30 and T60), and 30, 60, and 90 minutes after bypass
was discontinued (T90, T120, and T150). One milliliter of fetal
blood for gas, hemoglobin, hematocrit, electrolyte, glucose, and
lactate analysis was drawn from the fetal carotid artery at the same
time points and analyzed immediately with a Stat Profile Ultra
analyzer (Nova, Waltham, Mass). Three milliliters of arterial blood
for detection of endothelins 1, 2, and 3 and CRF plasma levels
were sampled at T0, T60, and T150; placed on ice in tubes
containing 100 L of ethylenediamine tetraacetic acid; and imme-
diately centrifuged at 5000g for 10 minutes. The plasma fraction
was then stored at 70°C until assayed. For the analysis, samples
were treated with an equal volume of 0.1% trifluoroacetic acid and
centrifuged at 1000g for 20 minutes, and the supernatant was
analyzed in triplicate by using enzyme immunoassay kits for
endothelins 1, 2, and 3 and CRF (Peninsula Laboratories Inc, San
Carlos, Calif). Pilot experiments did not show a significant differ-
ence in the results, with plasma samples extracted with C18 SEP
columns (data not shown). Endothelins and CRF were also mea-
sured in specimens obtained from the CVVHD dialysate fluid.
Data Analysis
Data are expressed as means  SD in the text and means  SE in
figures.
Data analysis was performed with nonparametric tests because
of the limited number of cases per group, which prevented analysis
of normality, by using the SPSS statistical package 8.0 (SPSS Inc,
Chicago, Ill). Statistical analysis to assess differences between
groups was performed in 2 steps. First, data were compared by
using the Kruskal-Wallis nonparametric test. If significant differ-
ences were found, treatment groups were compared individually
with the control group by using the Mann-Whitney U test.
Differences within groups at different time points were assessed
with the Wilcoxon signed-rank test (see Appendix B). All tests
are 2 sided.
To assess the overall tolerance of the procedure, we have
developed a score ranging from 5 to 35 that cumulates metabolic
and hemodynamic data from 7 different parameters, including
arterial pH, PaCO2, bicarbonate level (HCO3), arterial oxygen
saturation, lactate blood level, systolic arterial blood pressure, and
diastolic arterial blood pressure. The average score of each group
was then calculated and used to compare groups (Table 1).
Results
Groups were homogeneous with respect to fetal body
weight (group 1, 2.8 0.5 kg; group 2, 2.4 0.7 kg; group
3, 3.1 0.7 kg; group 4, 2.4 0.2 kg; P not significant).
On the first analysis of data, we observed a substantial
linear evolution of all analyzed parameters in all groups
during and after CB. Results are therefore presented only at
T0, at the end of CB (T60), and at the end of the experiment
(T150) to simplify the presentation and reading of the data.
Fetal Arterial Blood Gases
pH. Data on pH levels are shown in Figure 1, A. Initial
pH levels were comparable between groups. A significant
decrease by the end of the experiment was apparent in all
animals. Statistically significant differences compared with
levels in control animals were found only in the CVVHD
group during the CB, where the average pH level increased
significantly.
PaCO2. Data on PaCO2 are shown in Figure 1, B. Mean
PaCO2 levels increased regularly during the experimental
procedure. A significant increase in PaCO2 level at the end of
the experiment, when compared with baseline values, was
found in all groups (Appendix B).
HCO3. Data on HCO3 levels are shown in Figure 1,
C. Mean HCO3 levels at T0 were comparable between
groups. Maternal pretreatment with betamethasone ap-
peared to cause a decrease in circulating HCO3 levels that
became statistically different from that seen in control ani-
mals at both the end of the CB period and the end of the
experiment. In the CVVHD group HCO3 levels increased
significantly during the CVVHD but decreased rapidly once
the animals were disconnected from the circuit. Conversely,
the methylprednisolone group showed significantly in-
creased HCO3 levels by the end of the experiment com-
pared with baseline values (Appendix B).
Arterial oxygen saturation. Data on arterial oxygen sat-
uration are shown in Figure 1, D. Mean arterial oxygen
TABLE 1. Scoring table for overall performance definition
Score pH PaCO2 (mm Hg) HCO3
 (mmol/L) O2 Sat (%) Lactate (mmol/L) SBP (mm Hg) DBP (mm Hg)
1 7.10 60 20 30 12 40 30
2 7.10–7.20 51–60 20–22 30–45 10–12 40–50 30–35
3 7.21–7.30 41–50 23–25 46–60 7–9 51–60 36–40
4 7.31–7.40 30–40 26–28 61–75 4–6 61–70 41–45
5 7.40 30 28 75 4 70 45
Range of values and related scores are reported for each parameter used, including arterial pH, PaCO2, HCO3
, arterial oxygen saturation (O2Sat), lactate
blood level, systolic arterial blood pressure (SBP), diastolic arterial blood pressure (DBP).
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Figure 1. Fetal arterial blood gas trends expressed as means  SE. Open circles, control animals; filled circles,
treatment groups; shaded area, CB; O2 Sat, arterial oxygen saturation. *P < .05 (Mann-Whitney U test).
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saturation levels decreased to the same extent in all groups
during the experiment. The maternal betamethasone group
seemed to have the worst evolution compared with that seen
in the control animals, but results did not reach statistical
significance.
Fetal Hemodynamics and Biochemicals
Heart rate. Data on heart rate are shown in Figure 2, A.
Initial and final average fetal heart rates were similar in all
groups. Although not significantly, mean heart rate in-
creased in all groups compared with in control animals
during and at the end of the CB.
Systolic arterial blood pressure. Data on systolic arte-
rial blood pressure are shown in Figure 2, B. Mean systolic
arterial blood pressure was comparable at T0 in all groups.
A significant increase was measured during CB in the
betamethasone and methylprednisolone groups compared
with in the control animals. Systolic blood pressure de-
creased significantly by the end of the CB compared with at
baseline in the betamethasone and control groups (Appen-
dix B).
Glucose blood level. Data on glucose blood levels are
shown in Figure 2, C. Glucose levels increased throughout
the CB in all groups. When compared with control animals,
treated animals had less hyperglycemia.
Lactate blood level. Data on lactate blood levels are
shown in Figure 2, D. The average lactate blood levels were
comparable between all groups and increased significantly
during the experiment, with the exception of the CVVHD
group, in which lactate levels remained significantly stable
during dialysis but increased thereafter.
Endothelins and CRF Levels
The mean plasma levels of endothelin 1 were similar at T0
in all groups and remained comparable with levels in con-
trol animals throughout the whole experiment in the beta-
methasone group. Endothelin 1 levels were significantly
lower than those of control animals in the methylpred-
nisolone group by the end of the experiment. Endothelin
1 levels remained comparable with baseline values in
CVVHD-treated fetuses both during and after CB (Figure
3, A).
A similar trend was observed for endothelins 2 and 3 and
CRF. All values were statistically different during and after
CB in animals treated with CVVHD. Plasma endothelin 2
levels compared with levels in control animals were lower
and reached statistical significance at the end of CB in the
methylprednisolone group (Figure 3, B-D).
Endothelins and CRF were not detected in the dialysate
fluid from fetuses of the CVVHD group.
Overall Performance Assessment Score
A score was developed that included both hemodynamic
and metabolic parameters to rank groups according to their
overall performance during and after CB (see the “Meth-
ods” section). On the basis of this score, it appears that
CVVHD-treated animals performed better during CB but
worsened rapidly after discontinuation of the procedure.
Methylprednisolone-treated animals had the best score by
the end of the experiment (Figure 4).
Discussion
This study was designed to investigate the effect of steroid
treatment and CVVHD on fetal tolerance of CB and the
associated inflammatory response.
Inflammatory reaction during fetal CB has been shown to
produce fetoplacental dysfunction either directly through
neutrophil degranulation or mediated by interleukins and
other vasoactive substances produced after endothelial dam-
age.4-6,17 Pharmacologic agents, such as indomethacin and
high-dose steroids, administered before fetal CB have been
shown by Sabik and colleagues9,18 to improve placental
function at least in part by inhibiting the production of
vasoconstrictive prostaglandins.
The anti-inflammatory effect of glucocorticoids is also
well known and is regularly used during cardiopulmonary
bypass in clinical practice.10
In recent years, hemofiltration techniques during cardio-
pulmonary bypass have been diffusely adopted in pediatric
cardiac surgery11-13 to reduce the inflammatory response to
the bypass itself or to help clearing circulating cytokines
produced during the procedure.14-16 It has been shown that
hemofiltration can remove a wide variety of cytokines, most
likely by means of absorption rather than filtration across
the membrane.19-21
Our experimental set-up was planned to test directly
whether steroids, CVVHD, or both are efficient in improv-
ing the tolerance to fetal CB and in decreasing the associ-
ated inflammatory reaction. Moreover, CVVHD could also
be beneficial in preventing metabolic imbalances that de-
velop during CB.
Steroids were administered either to pregnant ewes 1 and
2 days before the experiment on the basis of protocols used
to promote fetal lung maturation in clinical practice or to the
fetuses before CB.
CB, which has been shown to cause a marked release of
endothelins in previous studies,6,22 was maintained for 60
minutes. The postbypass observation period was extended
to 90 minutes to evaluate the long-term tolerance and effects
of the various treatment regimens.
The miniaturized inline axial flow pump circuit signifi-
cantly reduces the extracorporeal surface and priming but
does not include an oxygenator.8 Despite the preservation of
fetal placental circulation, the absence of an oxygenator
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Figure 2. Fetal hemodynamic and biochemical trends expressed as means  SE. Open circles, control animals;
filled circles, treatment groups; shaded area, CB; HR, heart rate; SBP, systolic arterial blood pressure; glucose,
glucose blood level; lactate, lactate blood level. *P < .05 (Mann-Whitney U test).
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Figure 3. Fetal trends of plasma levels of vasoactive peptides expressed as means  SE. Open circles, control
animals; filled circles, treatment groups; shaded area, CB; ET, endothelin. *P < .05 (Mann-Whitney U test).
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during prolonged CB has most likely increased fetal oxygen
desaturation in our animals, which might have influenced
the overall tolerance of the procedure.
The inflammatory reaction was monitored by dosing
circulating plasma endothelins, which are produced on stim-
ulation by proinflammatory cytokines.23,24 The analysis of
other inflammatory and vasoactive mediators was limited by
the lack of commercially available detection kits that cross-
react with ewe peptides. Among these, CRF was chosen
because it has been shown to be a potent human placental
vasodilator through nitric oxide synthesis and release25 and
because its production might have been influenced by ma-
ternal or fetal steroid therapy. In particular, it has been
shown that maternal corticosteroid treatment suppresses hy-
pothalamic CRF secretion but increases placental CRF pro-
duction in vitro26 and in vivo,27 which is thought to promote
placental vasodilation and subsequent reactive increase in
fetal arterial blood pressure.28 These effects might be coun-
terbalanced by a reduction in fetal PaO2 caused by maternal
steroid treatment, as shown experimentally in sheep.29
The interpretation of our data has some limitations be-
cause they are obtained from a limited number of cases that
often yielded clear trends in evolution without reaching
statistical differences. These limitations are difficult to over-
come because of the complexity of the experimental setting,
which does not allow for using a large number of animals.
To overcome these limitations, at least in part, we have
developed a scoring system that includes a number of pa-
rameters known to be good estimators of the tolerance to
CB stress. These data show that fetal CB was best tolerated
during the bypass by CVVHD-treated animals but that
animals treated with methylprednisolone performed better
90 minutes after the end of the procedure.
Maternal steroid pretreatment was ineffective and even
deleterious to the fetoplacental unit. Higher fetal arterial
blood pressure and heart rate during CB, after CB, or both
and worse blood gases since the onset of the procedure in
these fetuses compared with in control animals might result
directly from maternal glucocorticoid treatment.29 CRF lev-
els did not differ significantly from those of the control
group and were not influenced by maternal treatment. Ap-
parently, worse hemodynamics at the beginning of the study
might have also influenced the initial tolerance of the pro-
cedure in these animals.
Fetuses treated with methylprednisolone appeared to
maintain better acid-base balance and arterial blood pres-
sure throughout the experiment when compared with con-
trol animals, which probably reflects a better preservation of
the fetoplacental unit after fetal steroid administration.
In the CVVHD group pH and bicarbonate levels were
well preserved during the CB by the dialytic effect of
CVVHD but decreased rapidly after the extracorporeal cir-
culation was discontinued. In this respect CVVHD appeared
to mask signs of placental dysfunction that might have been
caused by worse hemodynamics. In fact, despite the fact
that the CVVHD apparatus was mounted in countercurrent
to the CB line, the pump appeared to be performing at a
somewhat lesser level (loss of 20%-30% of the maximal
flow rate), possibly because of the higher compliance of the
system. In addition, partial hemodilution by the filter and
tubing priming volume and poor immunologic tolerance to
the human plasma protein solution that was used for prim-
ing might have contributed to the hemodynamic deteriora-
tion of this group of animals. Hemodilution, as assessed on
the basis of hematocrit values, did not exceed 6% and was
not statistically different from that of control fetuses (data
not shown).
Figure 4. Performance score analysis that cumulates metabolic
and hemodynamic data from 7 different parameters, including
arterial pH, PaCO2 (millimeters of mercury), HCO3
 (millimoles per
liter), arterial oxygen saturation (percentage), lactate blood level
(millimoles per liter), systolic arterial blood pressure (millimeters
of mercury), and diastolic arterial blood pressure (millimeters of
mercury). Open circles, control animals; triangles, maternal pre-
treatment with betamethasone; inverted triangles, fetal treatment
with methylprednisolone; filled squares, fetal CVVHD.
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The average blood glucose levels increased significantly
throughout CB within each group and decreased thereafter
to return to near-baseline values. The initial trend can be
attributed to fetal stress and was higher in the control group
when compared with that in the methylprednisolone and
CVVHD groups. The mean blood lactate levels were com-
parable between groups and increased progressively
throughout the experiment, with the exception of the CV-
VHD group, in which lactate levels remained stable during
dialysis but increased thereafter. Overall, progressive lactate
accumulation reflects increased anaerobic metabolism and
correlates well with the decrease in oxygen saturation. Be-
cause lactate diffuses readily across the polysulfone filter,
the initial lactate stability in the CVVHD group is likely to
be caused by increased lactate clearance rather then de-
creased production. This is also re-enforced by the fact that
these animals experienced a similar arterial desaturation
when compared with the other animals. Similarly, blood
glucose levels might have been balanced by the dialysate
solution glucose levels in the CVVHD group, partially
masking the hyperglycemic stress reaction to the CB.
The analysis of plasma endothelins and CRF levels
showed that maternal steroid pretreatment failed to decrease
the inflammatory release of these molecules. Fetal treatment
with methylprednisolone produced a moderate but signifi-
cant decrease of endothelin 2 production during CB and
endothelin 1 production at the end of the experiment, sup-
porting the efficacy of glucocorticoids in blocking proin-
flammatory cytokine production and secondary synthesis of
endothelins.10,23,24
In control animals, but not in steroid-treated fetuses,
circulating endothelins also continued to accumulate after
discontinuation of the CB, suggesting the activation of an
inflammatory loop.
Most significantly, however, we found a complete sup-
pression of endothelin accumulation in CVVHD fetuses that
was well maintained after discontinuation of the CB. On the
basis of the molecular weight and experimental data, some
believe that clearance of these molecules is achieved pri-
marily by absorption rather than a clearance across the
membrane.19-21 In fact, we were not able to detect endothe-
lins or CRF in the dialysate fluid, but these results are
hampered by the dilution in the volume of the dialysate,
which prevented accurate measurements at less than the
limits of detection of our assay.
Our data suggest that polysulfone membranes can clear
or inhibit the production of inflammatory and vasoactive
peptides from the bloodstream. Noticeably, however, clear-
ance by means of absorption is highly enhanced by the use
of net ultrafiltration forces, which we did not use. Taken
together with the fact that we did not observe a rebound of
endothelin accumulation after discontinuation of the CV-
VHD, it is possible that polysulfone membranes might have
been sufficient to remove even small amounts of molecules
produced in the initial phases of the reaction to the CB and
therefore have blocked the initiation of an inflammatory
amplification loop. Alternatively, polysulfone membranes
might have directly decreased production of inflammatory
mediators by stabilizing circulating inflammatory cells that
are otherwise activated through their passage into the ex-
tracorporeal circuit. This point deserves further investiga-
tion.
Conclusion
CVVHD provides sustained stability of plasma levels of
vasoactive substances during fetal CB. This technique
might help, possibly in association with fetal steroid treat-
ment, to contain the inflammatory response leading to post-
bypass placental dysfunction, which has been shown to be
crucial to allow future feasibility of open fetal cardiac
surgery.
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Appendix A. Perfusion Control
An indirect method was used to monitor the pump efficiency and
the perfusion condition on the basis of pressure measurements
(pressure transducers Truwave PX-600 F, Edwards Lifesciences)
in the bypass circuit upstream and downstream to the axial flow
pump (Hemopump, modified model HP24 sternotomy pump;
Medtronic Inc).
Assuming that the venous and arterial branches of the circuit
represent preload and afterload for the pump, respectively, these
loads constitute crucial settings to obtain the flow rate requested.
To study the pump flow rates for any possible loading condition,
an in vitro setup was designed to allow measurements of pump
inlet and outlet pressures and also pressure decrease along the
arterial cannula; a regression line was calculated from those data.
A gravimetric method was used to set the preload between 3 and
6 mm Hg and afterload in steps of 10 mm Hg by means of 2
constant head tanks. Thus a steady flow setup was provided to
determine pump efficiency within the same circuit used for fetal
CB. All the 7-step speed levels of the pump were selected, and
pressures and flows were recorded with pressure transducers
(Transpack; Abbott Healthcare, Ithaca, NY) and an electromag-
netic flowmeter (Handress & Hauser Italia, Cernusco, Italy) with a
0.1% accuracy at the arterial outlet. According to a preliminary
flow visualization of the pump function in a glass test bench,
pressure transducers were placed in positions where no flow sep-
aration or vorticity occurred.
From these recordings, tables and functions were obtained to
compare with the in vivo experimental data and to derive the
perfusion flow rate on the basis of pump preload, afterload, and
speed.
With the average mean right atrial pressure measured at the
steady state during CB being 5 mm Hg and the average mean
systemic blood pressure being 45 mm Hg, the maximal flow rate
obtained at the fastest pump speed was 1 L/min.
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